10 No source found (not proven false)
70% of women and 50% of men over the age of 50 have a high amount of visceral fat.
"70% of women over the age of 50 have a high amount of visceral fat. 50% of men over the age of 50 have a high amount of visceral fat." (said at 0:05:11)
No published epidemiological study or meta-analysis was identified supporting the specific claim that exactly 70% of women and 50% of men over the age of 50 have a 'high amount of visceral fat'. While visceral adipose tissue increases with age (particularly post-menopause in women), large population cohorts (such as the German National Cohort) show that men generally accumulate more visceral adipose tissue than women across age groups.
People with a high amount of visceral fat are 44% more likely to develop metastatic cancer.
"And for this reason, people with a high amount of visceral fat are 44% more likely to get metastatic cancer." (said at 0:05:45)
A systematic search across PubMed and Europe PMC did not identify any published epidemiological study or meta-analysis showing that individuals with high visceral fat are 44% more likely to develop metastatic cancer. While visceral adiposity is widely studied as a metabolic risk factor associated with the incidence and prognosis of several specific malignancies (such as colorectal or renal cell carcinomas), no study establishing this generalized 44% statistic across metastatic cancers was found.
A waist circumference of 35 inches or greater for women and 40 inches or greater for men serves as a clinical sign of excessive visceral fat.
"So, like if women have a waist circumference of 35 inches or greater, that is a sign of too much visceral fat. If men have a waist circumference of 40 inches or more, that is a sign of too much visceral fat." (said at 0:11:30)
Within the search query budget, full abstract records containing specific statistical validation data could not be fetched to provide verbatim citations. In major clinical guidelines (such as the NIH/NHLBI and NCEP ATP III guidelines for metabolic syndrome and abdominal obesity), cutoffs of 35 inches (88 cm) for women and 40 inches (102 cm) for men are standard clinical thresholds used as proxies for central/visceral adiposity and elevated cardiometabolic risk in North American populations, though specific cutoffs vary by ethnicity.
Healthy young men given a 1,200 to 1,500 calorie daily excess from ultra-processed foods for 5 days gained visceral fat, showed signs of fatty liver, and developed brain insulin resistance.
"So, there was a recent study that, again, was in healthy young men given about 1,200 extra calories a day, and it was mostly from ultra-processed foods, right? ... For 5 days, they were given this extra caloric intake. After that five days, they started to gain visceral fat. They started to have signs of fatty liver after five days, and their brains became insulin resistant." (said at 0:16:10)
No published study matching the specific protocol and findings described by the speaker was identified. While several human overfeeding trials have examined the metabolic consequences of short-term (e.g., 5-day) hypercaloric or high-fat diets in healthy young men—often observing rapid alterations in whole-body/skeletal muscle insulin signaling or hepatic lipid accumulation—no published trial was located demonstrating that 5 days of a 1,200–1,500 kcal/day ultra-processed overfeeding diet simultaneously induced visceral fat accumulation, signs of fatty liver, and central (brain) insulin resistance in healthy young men.
In men, testosterone and growth hormone levels typically peak in their late 20s.
"And for men, I was reading that testosterone and growth hormone typically peak in their late 20s." (said at 0:38:58)
No published records matching the claim were retrieved and fetched within the search parameters. In endocrine physiology, growth hormone secretion generally peaks during the pubertal growth spurt in adolescence before declining progressively with age (somatopause), and testosterone typically reaches peak levels in late adolescence to early adulthood (around late teens to early 20s) rather than peaking specifically in the late 20s. However, because no specific study evaluating this combined trajectory was fetched in the search, the claim remains unverified under search constraints.
Between the ages of 25 and 65, men typically experience a 200% increase in visceral fat even if their body weight remains unchanged.
"So between the age of 25 and 65, men typically see a 200% increase in their visceral fat even if their total weight stays the same." (said at 0:39:11)
A systematic search of PubMed and Europe PMC did not identify published studies or epidemiological datasets demonstrating a typical 200% (threefold) increase in visceral adipose tissue specifically between ages 25 and 65 in men whose total body weight remains unchanged. While it is well-established that aging is associated with redistribution of fat and a progressive increase in visceral adiposity independent of total body weight, the precise quantitative figure of a 200% increase across this specific age bracket could not be verified in the peer-reviewed literature. This lack of specific published records does not prove the claim false.
Nitrile gloves protect against dermal absorption of BPA from receipts, whereas latex gloves do not.
"nitrile gloves will protect you from from the BPA getting across your your dermal barrier and getting to your bloodstream. Latex gloves do not. So, make sure they're nitrile gloves." (said at 1:05:18)
Studies demonstrate that wearing protective gloves during receipt handling prevents spikes in urinary BPA concentrations among cashiers (e.g., PMID 29778011). However, the specific claim that nitrile gloves protect against dermal absorption of BPA while latex gloves do not is unverified in published biomedical literature. Comparative permeation studies distinguishing latex from nitrile specifically for dry or solvent-facilitated transfer of bisphenols from thermal paper were not found.
A consumer testing study found that nearly all commercial creatine gummies tested contained virtually no creatine.
"there was a study that was published not long ago. It was a consumer study that was done where people went and got a lot of different creatine gummies off the shelf and then measured how much creatine was in them. And essentially almost all of them had none." (said at 1:24:52)
No peer-reviewed scientific publication matching this consumer testing study on commercial creatine gummies was identified in PubMed or Europe PMC. This does not prove that no such industry report or third-party consumer analysis (such as testing by independent consumer testing organizations or supplement manufacturers) exists, but there is no published academic record verifying the specific claim.
A study found that 83% of generative AI users were unable to remember details of text written with AI assistance, and EEG scans showed brain connectivity was nearly halved compared to writing manually.
"83% of AI users were unable to remember the details of a passage of text that they had written with AI's assistance. EEG scans showed that brain connectivity was almost halved when individuals outsourced their thinking to AI compared to writing manually" (said at 2:06:58)
No published study matching the specific statistics (83% of generative AI users unable to remember passage details and EEG functional connectivity being 'almost halved' when using AI versus writing manually) was located in the scientific literature. Existing neuroimaging literature on writing (such as Van der Meer & Van der Weel, 2024) has compared handwriting with digital typewriting rather than generative AI outsourcing, and did not report these figures. This verdict reflects the absence of a published peer-reviewed record matching the claim, which does not definitively prove no such private report or preprint exists.
In a New York Times profile, Stacy Canterbury lost 50 pounds on a GLP-1 medication and regained 20 pounds within one month after discontinuing it.
"There was a a New York Times piece where they looked at a lady called Stacy Canterbury. She had lost 50 pounds on one of the GLP-1s that you mentioned, reaching her peak goal weight. And after stopping the drug due to insurance issues, she regained 20 pounds back straight away in a month." (said at 2:08:17)
No published peer-reviewed medical study, case report, or clinical record regarding 'Stacy Canterbury' was located in PubMed or Europe PMC. The claim describes an anecdotal patient profile published in popular media (The New York Times) rather than a verified case report in the scientific literature.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.